| Energy-stress-mediated AMPK activation inhibits ferroptosis H Lee, F Zandkarimi, Y Zhang, JK Meena, J Kim, L Zhuang, S Tyagi, L Ma, ... Nature cell biology 22 (2), 225-234, 2020 | 646 | 2020 |
| The spliceosome is a therapeutic vulnerability in MYC-driven cancer TYT Hsu, LM Simon, NJ Neill, R Marcotte, A Sayad, CS Bland, ... Nature 525 (7569), 384-388, 2015 | 456 | 2015 |
| Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer EA Bowling, JH Wang, F Gong, W Wu, NJ Neill, IS Kim, S Tyagi, ... Cell 184 (2), 384-403. e21, 2021 | 110 | 2021 |
| Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer JM Einstein, M Perelis, IA Chaim, JK Meena, JK Nussbacher, AT Tankka, ... Molecular cell 81 (15), 3048-3064. e9, 2021 | 101 | 2021 |
| Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer A Nair, HC Chung, T Sun, S Tyagi, LE Dobrolecki, R Dominguez-Vidana, ... Nature medicine 24 (4), 505-511, 2018 | 53 | 2018 |
| The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor KL Karlin, G Mondal, JK Hartman, S Tyagi, SJ Kurley, CS Bland, TYT Hsu, ... Cell reports 9 (4), 1318-1332, 2014 | 31 | 2014 |
| Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6 A Arnal-Estapé, WL Cai, AE Albert, M Zhao, LE Stevens, F López-Giráldez, ... Oncogene 39 (18), 3726-3737, 2020 | 12 | 2020 |
| DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells R Ramabadran, JH Wang, JM Reyes, AG Guzman, S Gupta, C Rosas, ... Nature cell biology 25 (4), 528-539, 2023 | 10 | 2023 |
| iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells H Bouguenina, S Nicolaou, YV Le Bihan, EA Bowling, C Calderon, ... Iscience 26 (7), 2023 | 1 | 2023 |
| Abstract A43: Deficiency of PTPRH in pediatric solid tumors identifies a high-risk phenotype that can be overcome by combinatorial tyrosine kinase inhibition KA Scorsone, S Tyagi, MC Orellana, S Gahlawat, A Nair, T Sun, ... Cancer Research 78 (19_Supplement), A43-A43, 2018 | 1 | 2018 |
| iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells H Bouguenina, S Nicolaou, YV Le Bihan, EA Bowling, C Calderon, ... iScience 27 (5), 2024 | | 2024 |
| Oncogenic ALK regulates cell cycle progression via CDK1: Implications for therapy KA Scorsone, S Gahlawat, S Tyagi, MC Orellana, TF Westbrook, ... Cancer Research 78 (13_Supplement), 4291-4291, 2018 | | 2018 |
| Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies RJ Bernardi, R Dominguez-Vidana, CS Bland, KA Scorsone, S Tyagi, ... Cancer Research 75 (15_Supplement), 738-738, 2015 | | 2015 |
